Search Results
Your search for Matthew Stenger matches 7673 pages
Showing 7601 - 7650Risk of Pancreatic Cancer May Be Reduced by Better Diet
In a study reported in the Journal of the National Cancer Institute, Hannah Arem, MHS, PhD, of the National Institutes of Health, and colleagues analyzed the association between quality of diet according to the 2005 Dietary Guidelines for Americans—Healthy Eating Index 2005...
NSABP B-38 Trial Shows No Benefit of Adding Fourth Drug to Standard Adjuvant Treatment in Women With Node-Positive Breast Cancer
Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. As reported in Journal of Clinical Oncology by Sandra M. Swain, MD, FACP, of Washington Cancer Institute–MedStar Washington Hospital Center, and colleagues,...
Night or Rotating Shift Work Associated With Increased Risk for High PSA
Some data support an association between circadian disruption and prostate cancer. In a study reported in Journal of the National Cancer Institute, Erin E. Flynn-Evans, PhD, of the Division of Sleep Medicine at Brigham and Women’s Hospital, and colleagues assessed the association between...
Study Determines Optimal Chemotherapy Regimen for Younger Patients With AML
In a study (Medical Research Council AML 15 Trial) reported in Journal of Clinical Oncology, Alan K. Burnett, MD, of Cardiff University School of Medicine and colleagues compared induction with daunorubicin/cytarabine, daunorubicin/cytarabine plus etoposide, and fludarabine/cytarabine/granulocyte...
No Progression-Free Survival Difference for Cediranib or Cediranib/Lomustine vs Lomustine in Recurrent Glioblastoma
In a phase III study (REGAL trial) reported in Journal of Clinical Oncology, Tracy T. Batchelor, MD, MPH, of Massachusetts General Hospital, and colleagues compared oral monotherapy with the pan-VEGF tyrosine kinase inhibitor cediranib and the combination of cediranib plus lomustine (CeeNu) vs...
Similar 10-Year Survival in Patients With Early-Onset BRCA1-Negative and BRCA1-Positive Breast Cancer
In a study reported in Journal of Clinical Oncology, Tomasz Huzarski, MD, PhD, of Pomeranian Medical University, Szczecin, Poland, and colleagues from the Polish Hereditary Breast Cancer Consortium assessed survival among women with early-onset breast cancer with and without BRCA1 mutation and...
Risk-Directed Treatment Intensification Significantly Improves Outcomes in Children With ALL and Intrachromosomal Amplification of Chromosome 21
In a study reported in Journal of Clinical Oncology, Anthony V. Moorman, PhD, of Newcastle University, and colleagues compared outcomes in children and adolescents with B-cell precursor acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21) in a trial in...
Intrachromosomal Amplification of Chromosome 21 Associated With Poor Outcome in Children With ALL
Intrachromosomal amplification of a region of chromosome 21 (iAMP21; three or more extra copies of RUNX1 on an abnormal chromosome 21) is a recently identified recurrent genomic abnormality associated with poorer outcome in acute lymphoblastic leukemia (ALL). In a study reported in Journal of...
Finasteride Reduces Risk of Low-Grade Prostate Cancer With No Impact on Long-Term Survival
In the Prostate Cancer Prevention Trial (PCPT), initially reported in 2003, finasteride significantly reduced the risk of prostate cancer by 24.8% but was associated with a relative 26.9% increase in risk of high-grade disease compared with placebo. In a study reported in The New England Journal of ...
No Invasive Disease-Free Survival Benefit of Adding Bevacizumab to Adjuvant Chemotherapy in Triple-Negative Breast Cancer
In a study (the BEATRICE trial) reported in Lancet Oncology, David Cameron, MD, of the University of Edinburgh, and colleagues evaluated the strategy of adding the antiangiogenic agent bevacizumab (Avastin) to adjuvant chemotherapy in women with triple-negative breast cancer. The study showed that...
Addition of Sunitinib to Capecitabine Does Not Improve Outcome in Previously Treated Metastatic Breast Cancer
A trial reported in Journal of Clinical Oncology by John P. Crown, MD, of the Irish Cooperative Oncology Research Group, and colleagues assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to capecitabine (Xeloda) in patients with previously treated metastatic breast cancer who...
Cancer Incidence Trends in Asian American Populations Indicate Need for Increased Prevention and Surveillance
In a report published in Journal of the National Cancer Institute, Scarlett Lin Gomez, PhD, of the Cancer Prevention Institute of California, and colleagues detailed cancer incidence trends among Asian American populations from 1990 through 2008. The findings indicate a need for increased...
Combined Microsatellite Instability and BRAF Status a Potential Marker of Risk Stratification in Colorectal Cancer
In a study reported in Journal of the National Cancer Institute, Paul Lochhead, MBChB,MRCP, of the Dana-Farber Cancer Institute and Harvard Medical School, and colleagues analyzed the association of microsatellite instability and BRAF status subgroups with survival in patients with colorectal...
Meta-Analysis Indicates Addition of Taxane to Cisplatin/5-FU Induction Improves Outcome in Locally Advanced Head and Neck Cancers
Cisplatin plus fluorouracil (5-FU) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and 5-FU in randomized trials in locoregionally advanced head and neck cancers. An updated individual patient data meta-analysis reported in the Journal of Clinical Oncology ...
Circulating Estrogens and Androgens Are Associated With Breast Cancer Risk in Premenopausal Women
In a study reported in Lancet Oncology, Timothy Key, PhD, of Oxford University, and colleagues in the Endogenous Hormones and Breast Cancer Collaborative Group analyzed data from seven prospective studies to determine associations between sex hormones and risk of breast cancer in premenopausal...
Cohort Analysis Shows Adjuvant Tamoxifen Reduces Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
In a study reported in Journal of Clinical Oncology, Kelly-Anne Phillips, MD, of Peter MacCallum Cancer Centre and University of Melbourne, and colleagues analyzed the association of adjuvant tamoxifen use and risk of contralateral breast cancer among women carrying BRCA1 and BRCA2 mutations in the ...
No Benefit/Detriment of New Donor in Second Hematopoietic Stem Cell Transplantation for Leukemia Relapse
Minimal data are available on outcomes of second allogeneic hematopoietic stem cell transplantation from unrelated donors after first hematopoietic stem cell transplantation in patients with hematologic relapse of acute leukemia. In a study reported in Journal of Clinical Oncology, Maximilian...
Metformin Use Reduces All-Cause and Prostate Cancer–Specific Mortality in Men With Diabetes
In a study reported in Journal of Clinical Oncology, David Margel, MD, PhD, of University of Toronto, and colleagues examined the effect of duration of antidiabetic medication exposure after prostate cancer diagnosis on all-cause and prostate cancer–specific mortality in men with diabetes....
Dabrafenib Active in BRAF-600E/K Mutant Metastatic Melanoma
In a phase II study (BREAK-2) reported in Journal of Clinical Oncology, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori Fondazione G. Pascale, and colleagues assessed the activity of the mutated BRAF kinase inhibitor dabrafenib (Tafinlar) in patients with BRAF-V600E/K mutant metastatic...
No Difference in Outcome With Purged vs Nonpurged Peripheral Blood Stem Cell Transplantation in High-Risk Neuroblastoma
The contribution of purging of peripheral blood stem cells to outcome of autologous stem cell transplantation in high-risk neuroblastoma has not been defined. In a trial (COG A3973) reported in Lancet Oncology by Susan G. Kreissman, MD, of Duke University Medical Center, and colleagues, children...
No Additional Benefit of Double Endocrine Treatment After Progression on Aromatase Inhibitors in Advanced Hormone Receptor–Positive Breast Cancer
In the SoFEA trial, reported in Lancet Oncology by Stephen R.D. Johnston, PhD, FRCP, of Royal Marsden NHS Foundation Trust, and colleagues, postmenopausal women with advanced hormone receptor–positive breast cancer that progressed on nonsteroidal aromatase inhibitors were treated with the...
Lenalidomide plus Dexamethasone Delays Progression and Improves Survival in High-risk Smoldering Multiple Myeloma
In a study reported in The New England Journal of Medicine, María-Victoria Mateos, MD, PhD, of the Universidad de Salamanca, and colleagues compared induction lenalidomide (Revlimid) plus dexamethasone followed by maintenance lenalidomide with observation in patients with high-risk...
Benefit Seen with Both Autologous and Allogeneic Hematopoietic Cell Transplantation in T-cell Non-Hodgkin Lymphoma
In a report in Journal of Clinical Oncology, Sonali M. Smith, MD, of University of Chicago Hospitals, and colleagues analyzed outcomes in a large cohort of autologous or allogeneic hematopoietic cell transplantation recipients with the most common T-cell non-Hodgkin lymphoma histologies. Their ...
Low-dose CT Screening for Lung Cancer: Details of First Round of Screening in National Lung Screening Trial
The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also...
Swedish Initiative Results in Significant Reduction in Inappropriate Prostate Cancer Imaging
A number of initiatives have been implemented to encourage reduction of inappropriate use of imaging to stage incident prostate cancer. Since 2000, the National Prostate Cancer Register (NPCR) of Sweden has led an effort to decrease national rates of inappropriate prostate cancer imaging by...
Particulate Matter Air Pollution Contributes to Increased Risk of Lung Cancer in Europe
Ambient air pollution has been associated with lung cancer risk. In a study reported in Lancet Oncology by Ole Raaschou-Nielsen, PhD, of the Danish Cancer Society Research Center, and colleagues, lung cancer incidence in European countries was prospectively assessed according to several measures of ...
No Benefit of Adding Atrasentan to Docetaxel in Advanced Castration-resistant Prostate Cancer
The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer, and the investigational endothelin receptor antagonist atrasentan has shown activity in prostate cancer. In the SWOG S0421 trial reported in Lancet Oncology by David I. Quinn, FRACP, of...
Docetaxel Superior to Erlotinib in Second-line Treatment of Advanced NSCLC with Wild-type EGFR
There is ongoing debate about the efficacy of erlotinib (Tarceva) in patients with advanced non–small cell lung cancer (NSCLC) whose tumors have wild-type EGFR. In the TAILOR trial, reported in Lancet Oncology by Marina Chiara Garassino, MD and colleagues, erlotinib was compared with standard ...
Study Evaluates Therapeutic Impact of Laparoscopic Para-aortic Staging Surgery before Chemoradiotherapy in Cervical Cancer
In a study reported in Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy, and colleagues evaluated survival outcomes in locally advanced cervical cancer patients with negative PET-CT imaging results who underwent laparoscopic para-aortic staging surgery before...
No Difference in Event-free Survival with Chemotherapy before vs after Radiation Therapy in Children with High-risk Medulloblastoma
A number of different strategies for combining chemotherapy and radiation therapy have been evaluated in the effort to improve survival in patients with high-risk medulloblastoma. In a trial (POG 9031) reported in Journal of Clinical Oncology, Nancy J. Tarbell, MD, of Massachusetts General Hospital ...
Molecular Profiling Improves Classification of Nodal Peripheral T-cell Lymphomas
The differential diagnosis of the most common peripheral T-cell lymphoma subtypes is difficult. In a phase III diagnostic accuracy study reported in Journal of Clinical Oncology, Pier Paolo Piccaluga, MD, PhD, of the University of Bologna, and colleagues in the European T-cell Lymphoma Study Group...
National Lung Screening Trial Analysis Supports Risk-based Targeting of Smokers for Low-dose CT Screening
The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung cancer mortality compared with chest radiography in participants aged 55 to 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since...
Radium-223 Dichloride Prolongs Overall Survival in Men with Metastatic Prostate Cancer in Phase III ALSYMPCA Trial
In a trial (ALSYMPCA) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, United Kingdom, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and...
Female Survivors of Childhood Cancer Have Increased Risk of Infertility
Decreased pregnancy rates and early menopause have been reported in female cancer survivors, although there is less information on infertility rates and reproductive interventions in these patients. In a study reported in Lancet Oncology, Sara E. Barton, MD, of Brigham and Women’s Hospital...
Adenovirus-mediated Gene Therapy with Sitimagene Ceradenovec Prolongs Median Time to Death or Reintervention in Adult Glioblastoma
In an open-label phase III trial (ASPECT) reported in Lancet Oncology, Manfred Westphal, MD, of University Hospital Eppendorf in Hamburg, and colleagues assessed the effects of locally applied adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir after...
Progesterone and Estrogen Receptor Expression Are Prognostic Markers for Endometrioid and High-grade Serous Ovarian Cancer
Few markers of ovarian cancer prognosis have been established, perhaps because potential subtype associations are missed in studies including patients with all histopathologic subtypes. In a study reported in Lancet Oncology, Weiva Sieh, PhD, of Stanford University and colleagues assessed the...
American Ginseng Improves Cancer-related Fatigue
In a collaborative phase III trial of the North Central Cancer Treatment Group and Mayo Clinic reported in Journal of the National Cancer Institute by Debra L. Barton, RN, PhD, of the Mayo Clinic, and colleagues, patients with cancer-related fatigue were treated with Wisconsin ginseng (a common...
Accelerated Partial-breast Irradiation Using 3D Conformal Radiation Therapy Causes More Adverse Events Compared with Whole-breast Irradiation
The RAPID trial compared accelerated partial-breast irradiation using three-dimensional (3D) conformal external-beam radiation therapy vs whole-breast irradiation in women with invasive or in situ breast cancer ≤ 3 cm. As reported by Ivo A. Olivotto, MD, FRCPC, of the British Columbia Cancer...
Bevacizumab/Pemetrexed Maintenance Increases Progression-free Survival vs Bevacizumab Alone in Advanced Nonsquamous NSCLC
Maintenance therapy is associated with improved survival in non–small cell lung cancer (NSCLC), but few studies have compared active agents in this setting. In a phase III trial (AVAPERL trial) reported in Journal of Clinical Oncology by Fabrice Barlesi, MD, PhD, of Aix Marseille...
Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC
In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final...
Obinutuzumab Shows Activity in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma and Indolent Non-Hodgkin Lymphoma
Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices ...
Whole-exome Sequencing of the NCI-60 Cell Line Panel Provides a Genomic Resource for Cancer Biology and Systems Pharmacology
The NCI-60 cell lines, which represent cancers of lung, colon, brain, ovary, breast, prostate, and kidney as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As...
Addition of Aflibercept to Docetaxel/Prednisone Does Not Improve Overall Survival in Men with Metastatic Castration-resistant Prostate Cancer
In a phase III double-blind study (VENICE trial) reported in Lancet Oncology, Ian F. Tannock, DSc, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the addition of the antiangiogenic agent aflibercept (Zaltrap) to standard docetaxel/prednisone therapy in patients with...
Addition of Panitumumab to Cisplatin/Fluorouracil Improves Progression-free Survival in Patients with Recurrent or Metastatic Head and Neck Cancer
Previous studies have shown that anti-EGFR monoclonal antibody treatment can improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In the open-label phase III SPECTRUM trial, Jan B. Vermorken, MD, of Antwerp University Hospital and...
Afatinib Prolongs Progression-free Survival Compared with Cisplatin plus Pemetrexed in EGFR-mutant Advanced Lung Adenocarcinoma
Afatinib is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has exhibited broad-spectrum activity against EGFR mutations in preclinical studies. A phase II study of afatinib in EGFR-mutation positive lung adenocarcinoma showed...
Bladder-sparing Trimodal Chemotherapy Produces Good Response in Patients with Muscle-invasive Bladder Cancer
In a phase II study reported in Lancet Oncology, Timur Mitin, MD, of Massachusetts General Hospital, and colleagues assessed the effects of adding paclitaxel or fluorouracil (5-FU) to radiation therapy plus cisplatin followed by adjuvant chemotherapy in a program of selected bladder preservation in ...
High Prediagnosis Red Meat Consumption Associated with Increased All-cause Mortality in Patients with Colorectal Cancer
There is evidence that diets high in red and processed meat are associated with increased risk of colorectal cancer. In a study reported in Journal of Clinical Oncology, Marjorie L. McCullough, ScD, and colleagues from the Epidemiology Research Program of the American Cancer Society examined the...
Volumetric Growth Rate of Small Colorectal Polyps on CT Colonography May Be Useful Risk Marker
The growth rates and clinical importance of small colorectal polyps have not been well established. In a study reported in Lancet Oncology, Perry J. Pickhardt, MD, of the University of Wisconsin School of Medicine and Public Health, and colleagues found that volumetric growth rate on computed...
Height Differences May Explain Excess Cancer Risk for Men
Most cancers occur more frequently in men than in women and greater height has been associated with increased risk for some cancers. In a study reported in Journal of the National Cancer Institute, Roland B. Walter, MD, PhD, of the Fred Hutchinson Cancer Research Center, and colleagues found that...
L1CAM Predicts Recurrence and Poor Outcome in Early-stage Type I Endometrial Cancer
Although patients with early-stage type I endometrial cancer have very good prognosis, a substantial proportion experience recurrence and die from the disease. In a study published in Journal of the National Cancer Institute, Alain G. Zeimet, MD, PhD, of Innsbruck Medical University, Austria, and...
